Want to see HK:9966 full AI Analyst Report?
9966 Stock Chart & Stats
HK$11.90
-HK$0.05(-1.46%)
At close: 4:00 PM EST
HK$11.90
-HK$0.05(-1.46%)
Day’s Range― - ―
52-Week RangeHK$6.02 - HK$15.75
Previous CloseN/A
Volume1.49M
Average Volume (3M)3.94M
Market Cap
HK$6.77B
Enterprise ValueHK$5.83B
Total Cash (Recent Filing)HK$1.35B
Total Debt (Recent Filing)HK$123.03M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding974,381,700
10 Day Avg. Volume3,868,184
30 Day Avg. Volume3,937,702
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)4.94
Price to Sales (P/S)15.34
P/FCF Ratio-55.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)HK$392.45M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA ~77% gross margin is structurally supportive for a biologics firm: it indicates strong product-level economics and pricing power. High gross margins give room to invest in R&D and commercialization while preserving operating leverage if revenue growth resumes.
Low Financial LeverageDebt-to-equity near 0.07 implies a conservatively levered balance sheet, reducing interest burdens and extending runway. Low leverage increases flexibility to finance clinical programs, enter partnerships, or absorb setbacks without urgent refinancing pressure.
Oncology Biologics-focused PipelineA focused monoclonal antibody and immuno-oncology strategy targets a structurally growing market with high barriers to entry. Success in this area can generate durable revenue streams and premium margins, aligning R&D efforts with long-term demand trends in oncology.
Bears Say
Volatile Revenue And Return To LossesA ~30% revenue drop and a return to ~111M net loss in 2025 show earnings instability. Persistent volatility undermines the company’s ability to plan commercialization spending, attract stable partners, and demonstrates execution risk that can persist across multiple quarters.
Unstable Cash Generation / Renewed Cash BurnThe shift from positive cash flow in 2024 to ~-122M operating and ~-153M free cash flow in 2025 raises funding sensitivity. Continued cash burn increases reliance on external financing, heightens dilution risk, and constrains strategic investments in late-stage trials or commercialization.
Loss-making With No Dividend IncomeBeing loss-making and offering no dividend limits the investor base to risk-tolerant stakeholders and ties valuation to clinical and approval outcomes. This structural dependency on binary R&D events raises long-term execution and financing risk until profitability is restored.
Alphamab Oncology News
9966 FAQ
What was Alphamab Oncology’s price range in the past 12 months?
Alphamab Oncology lowest stock price was HK$6.02 and its highest was HK$15.75 in the past 12 months.
What is Alphamab Oncology’s market cap?
Alphamab Oncology’s market cap is HK$6.77B.
When is Alphamab Oncology’s upcoming earnings report date?
Alphamab Oncology’s upcoming earnings report date is Aug 20, 2026 which is in 49 days.
How were Alphamab Oncology’s earnings last quarter?
Alphamab Oncology released its earnings results on Mar 25, 2026. The company reported -HK$0.154 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.154.
Is Alphamab Oncology overvalued?
According to Wall Street analysts Alphamab Oncology’s price is currently Overvalued.
Does Alphamab Oncology pay dividends?
Alphamab Oncology does not currently pay dividends.
What is Alphamab Oncology’s EPS estimate?
Alphamab Oncology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alphamab Oncology have?
Alphamab Oncology has 974,381,700 shares outstanding.
What happened to Alphamab Oncology’s price movement after its last earnings report?
Alphamab Oncology reported an EPS of -HK$0.154 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.98%.
Which hedge fund is a major shareholder of Alphamab Oncology?
Currently, no hedge funds are holding shares in HK:9966
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alphamab Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
239.25%
12-Months-Change
Fundamentals
Return on Equity
-6.26%
Trailing 12-Months
Asset Growth
-2.09%
Trailing 12-Months
Company Description
Alphamab Oncology
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
Technical Analysis
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---